Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Agilent Technologies Launch SurePrint G3 Microarray
April 20, 2009
- Merck Serono: Gonalef Subcutaneous Injection Pen
April 20, 2009
- Eisai Licenses Out Gliadel Wafer to Nobelpharma
April 20, 2009
- BUSINESS NEWS IN BRIEF
April 20, 2009
- Actavis ASKA Aims at Sales of ¥10 Bil. by 2015
April 13, 2009
- JKMA Publishes English Terminology for Kampo Medicines
April 13, 2009
- Co-DIO, Ecard Jump to 1st and 2nd Place on GP Market: Rep Track Survey
April 13, 2009
- 22 Companies to Apply for NHI Price Listing for Generics of Cravit
April 13, 2009
- Council to Focus on Differences in Prices of Medical Devices in Japan and Abroad
April 13, 2009
- Pharmacists Hold Key to Promotion of the Use of Generics: Mr Isobe
April 13, 2009
- MEDICAL DEVICE NEWS IN BRIEF
April 13, 2009
- Hansha's Sales Forces May Help Generics Makers Provide Information
April 13, 2009
- JCS (Japanese Circulation Society) 2009
April 13, 2009
- Mylan Seiyaku Kicks Off Cancer-Specialized Team
April 13, 2009
- Lucentis to Become the Mainstay for AMD in Japan as Well
April 13, 2009
- Society of Applied Therapeutics to Be Inaugurated
April 13, 2009
- Optimal Antiviral Therapy Important to Prevent Liver Cancer: Dr Izumi
April 13, 2009
- Daiichi Sankyo to Apply for DU-176b as Japan's First Oral Anti-Xa Agent
April 13, 2009
- Synergistic Effects Can Be Expected with Adoair
April 13, 2009
- Daiichi Sankyo Reshuffles R&D Structures to Quickly Develop Biologics
April 13, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…